Harald Nusser

Head of Global Health and Health Equity, Merck

Head, Gilead Sciences, Global Patient Solutions, since May 2021, in that capacity being responsible for 96 LMLICs commercially with a dual goal of working towards Global Health Equity and towards private sector engagement in SDG achievement. Before that, Head, Novartis Social Business being with Sandoz International since June 2015 to lead Novartis Access, which merged with legacy access to medicines programmes of the company into the unit Social Business during 2016. Started career at Schering in 2000 as a mathematician in the global R&D function. Having worked in both exploratory research as well as clinical research, held positions of increasing responsibility in Strategic Planning in both Schering and Bayer between 2004 and 2010. As Head, Portfolio Management, managed the Holistic R&D Portfolio Review for Bayer Pharma and the annual Strategic Planning Process for Bayer HealthCare, led restructuring activities and became Managing Director for Bayer in Slovakia in 2010. Starting in 2012, led the Bayer HealthCare business (comprising Animal Health, Radiology, Diabetes Care, OTC and Pharmaceuticals) in sub-Saharan Africa, Uruguay, Paraguay, Bolivia, Peru, Laos, Myanmar and Cambodia before joining Sandoz International in June 2015 as Global Head, Novartis Access. 1998, PhD in Mathematics from the Free University of Berlin; 2003, MBA from the University of Bradford, United Kingdom.

Sobre nosostros



Socios y Miembros

  • Únete

Ediciones en otros idiomas

Política de privacidad y normas de uso

© 2024 Foro Económico Mundial